Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf’s New Spin On US FDA Staffing: Attrition Rate Is Too Low

Executive Summary

Commissioner also talks drug shortages, difficulty getting key agency and industry priorities done in new pandemic legislation, and how legal challenges to FDA authority could impact pharma companies desire to develop new medicines.

You may also be interested in...



US FDA Could Have Millions Of Advisors, If Not For Current Law, Califf Says

Commissioner Califf says the technology exists and the idea would allow the agency to be more nimble, but the Paperwork Reduction Act makes the process difficult.

Califf’s Top Priorities For New Year: Misinformation And Evidence Generation

FDA Commissioner is ‘pretty excited’ about obtaining high quality evidence in the postmarket space, noting agency's collaboration with NIH. He cites need to address the low cost of generic drugs as a factor in drug shortages.

CBER’s New Gene Therapy Office Director Is Former Blood Research Office Chief Verdun

Nicole Verdun, who had been running the CBER Office of Blood Research and Review, now is director of the center’s Office of Therapeutic Products. She will manage OTP’s growing head count, as well as its increasing workload.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel